ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target

News   May 17, 2013

 
ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target
 
 
 

RELATED ARTICLES

Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UK

News

Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK. Award made as part of UK’s Innovation Agency’s Industrial Strategy boost for UK medicines with £70m of funding to help develop new treatments.

READ MORE

Latent HIV Reservoirs Inherently Resistant to Elimination by CD8+ T-cells

News

The latest “kick-and-kill” research to eliminate the HIV virus uncovered a potential obstacle in finding a cure. A recent study found that latent HIV reservoirs show resistance to CD8+ T-cells, a type of white blood cell whose primary function is to kill infected cells.

READ MORE

LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target Discovery

News

LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Cell Science Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE